251 related articles for article (PubMed ID: 24139347)
1. Effects of 5-year treatment with testosterone undecanoate on lower urinary tract symptoms in obese men with hypogonadism and metabolic syndrome.
Francomano D; Ilacqua A; Bruzziches R; Lenzi A; Aversa A
Urology; 2014 Jan; 83(1):167-73. PubMed ID: 24139347
[TBL] [Abstract][Full Text] [Related]
2. Testosterone supplementation does not worsen lower urinary tract symptoms.
Pearl JA; Berhanu D; François N; Masson P; Zargaroff S; Cashy J; McVary KT
J Urol; 2013 Nov; 190(5):1828-33. PubMed ID: 23764078
[TBL] [Abstract][Full Text] [Related]
3. Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 36 months controlled study.
Aversa A; Bruzziches R; Francomano D; Greco EA; Fornari R; Di Luigi L; Lenzi A; Migliaccio S
Aging Male; 2012 Jun; 15(2):96-102. PubMed ID: 22439807
[TBL] [Abstract][Full Text] [Related]
4. Effects of 8-Year Treatment of Long-Acting Testosterone Undecanoate on Metabolic Parameters, Urinary Symptoms, Bone Mineral Density, and Sexual Function in Men With Late-Onset Hypogonadism.
Permpongkosol S; Khupulsup K; Leelaphiwat S; Pavavattananusorn S; Thongpradit S; Petchthong T
J Sex Med; 2016 Aug; 13(8):1199-211. PubMed ID: 27436076
[TBL] [Abstract][Full Text] [Related]
5. Hypogonadal men with moderate-to-severe lower urinary tract symptoms have a more severe cardiometabolic risk profile and benefit more from testosterone therapy than men with mild lower urinary tract symptoms.
Saad F; Doros G; Haider KS; Haider A
Investig Clin Urol; 2018 Nov; 59(6):399-409. PubMed ID: 30402573
[TBL] [Abstract][Full Text] [Related]
6. Concurrent improvement of the metabolic syndrome and lower urinary tract symptoms upon normalisation of plasma testosterone levels in hypogonadal elderly men.
Haider A; Gooren LJ; Padungtod P; Saad F
Andrologia; 2009 Feb; 41(1):7-13. PubMed ID: 19143723
[TBL] [Abstract][Full Text] [Related]
7. Voiding function improves under long-term testosterone treatment (TTh) in hypogonadal men, independent of prostate size.
Yassin A; Alwani M; Al-Zoubi RM; Aboumarzouk OM; Talib R; Nettleship J; Kelly D; Albaba B
Int Urol Nephrol; 2023 Jul; 55(7):1649-1658. PubMed ID: 37148486
[TBL] [Abstract][Full Text] [Related]
8. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study.
Aversa A; Bruzziches R; Francomano D; Rosano G; Isidori AM; Lenzi A; Spera G
J Sex Med; 2010 Oct; 7(10):3495-503. PubMed ID: 20646185
[TBL] [Abstract][Full Text] [Related]
9. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men.
Zitzmann M; Mattern A; Hanisch J; Gooren L; Jones H; Maggi M
J Sex Med; 2013 Feb; 10(2):579-88. PubMed ID: 22812645
[TBL] [Abstract][Full Text] [Related]
10. Type 2 diabetes but not metabolic syndrome is associated with an increased risk of lower urinary tract symptoms and erectile dysfunction in men aged <45 years.
Wang CC; Chancellor MB; Lin JM; Hsieh JH; Yu HJ
BJU Int; 2010 Apr; 105(8):1136-40. PubMed ID: 19804425
[TBL] [Abstract][Full Text] [Related]
11. Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life.
Yassin DJ; Doros G; Hammerer PG; Yassin AA
J Sex Med; 2014 Jun; 11(6):1567-76. PubMed ID: 24712761
[TBL] [Abstract][Full Text] [Related]
12. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters.
Yassin A; Nettleship JE; Talib RA; Almehmadi Y; Doros G
Aging Male; 2016; 19(1):64-9. PubMed ID: 26742589
[TBL] [Abstract][Full Text] [Related]
13. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study).
Hackett G; Cole N; Bhartia M; Kennedy D; Raju J; Wilkinson P; Saghir A;
Int J Clin Pract; 2014 Feb; 68(2):203-15. PubMed ID: 24355040
[TBL] [Abstract][Full Text] [Related]
14. The relationship between lower urinary tract symptoms/benign prostatic hyperplasia and the number of components of metabolic syndrome.
Park YW; Kim SB; Kwon H; Kang HC; Cho K; Lee KI; Kim YJ; Lee JH
Urology; 2013 Sep; 82(3):674-9. PubMed ID: 23850334
[TBL] [Abstract][Full Text] [Related]
15. Testosterone treatment and change of categories of the International prostate symptom score (IPSS) in hypogonadal patients: 12 years prospective controlled registry study.
Yassin A; Kelly D; Nettleship J; Talib R; Al-Zoubi RM; Aboumarzouk OM; Albaba B
Aging Male; 2023 Dec; 26(1):2220567. PubMed ID: 37287273
[TBL] [Abstract][Full Text] [Related]
16. Improved Lower Urinary Tract Symptoms Associated With Testosterone Replacement Therapy in Japanese Men With Late-Onset Hypogonadism.
Okada K; Miyake H; Ishida T; Sumii K; Enatsu N; Chiba K; Matsushita K; Fujisawa M
Am J Mens Health; 2018 Sep; 12(5):1403-1408. PubMed ID: 27256990
[TBL] [Abstract][Full Text] [Related]
17. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome.
Giltay EJ; Tishova YA; Mskhalaya GJ; Gooren LJ; Saad F; Kalinchenko SY
J Sex Med; 2010 Jul; 7(7):2572-82. PubMed ID: 20524974
[TBL] [Abstract][Full Text] [Related]
18. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men.
Debruyne FM; Behre HM; Roehrborn CG; Maggi M; Wu FC; Schröder FH; Jones TH; Porst H; Hackett G; Wheaton OA; Martin-Morales A; Meuleman E; Cunningham GR; Divan HA; Rosen RC;
BJU Int; 2017 Feb; 119(2):216-224. PubMed ID: 27409523
[TBL] [Abstract][Full Text] [Related]
19. Beneficial effects of testosterone administration on symptoms of the lower urinary tract in men with late-onset hypogonadism: a pilot study.
Kalinchenko S; Vishnevskiy EL; Koval AN; Mskhalaya GJ; Saad F
Aging Male; 2008 Jun; 11(2):57-61. PubMed ID: 18570056
[TBL] [Abstract][Full Text] [Related]
20. Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median followup of 3 registries.
Haider A; Zitzmann M; Doros G; Isbarn H; Hammerer P; Yassin A
J Urol; 2015 Jan; 193(1):80-6. PubMed ID: 24980615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]